Lysette Iglesias, MD
Pediatric Endocrinology · Miami Lakes, FLNPI 1073749057
Payments from drug & device makers
Across 104 payments — averaging $17.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$428
- Lilly USA, LLC$339
- Boehringer Ingelheim$215
- Novo Nordisk$151
- AstraZeneca$104
- Sanofi-aventis U.S. LLC$81
- plus $528 from 17 others
What the payments were for
- Food & beverage$1,80698%
- Education$402%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 25 | $428 |
| Lilly USA, LLC | 24 | $339 |
| Boehringer Ingelheim | 11 | $215 |
| Novo Nordisk | 7 | $151 |
| AstraZeneca(2 entities) | 6 | $104 |
| Sanofi-aventis U.S. LLC | 3 | $81 |
| Merck | 5 | $79 |
| Amgen | 3 | $70 |
| Insulet Corporation | 2 | $48 |
| Abbott | 3 | $44 |
| Neurocrine Biosciences, Inc. | 2 | $37 |
| Amneal Pharmaceuticals LLC | 2 | $32 |
| Madrigal Pharmaceuticals | 1 | $30 |
| Sobi, Inc | 1 | $24 |
| Dexcom, Inc. | 1 | $22 |
| Eton Pharmaceuticals, Inc. | 1 | $20 |
| Novartis | 1 | $20 |
| Ascendis Pharma Endocrinology Inc | 1 | $20 |
| IBSA Pharma Inc. | 1 | $20 |
| Xeris Pharmaceuticals, Inc. | 1 | $20 |
| Corcept Therapeutics | 1 | $17 |
| Mannkind Corporation | 1 | $14 |
| Johnson & Johnson | 1 | $12 |
How this compares
$1,846 in reported general payments places this provider in the 40th percentile of 102 pediatric endocrinology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 193 | $153,363 |
| TrulicityDulaglutide | 114 | $112,209 |
| OzempicSemaglutide | 101 | $99,079 |
| MounjaroTirzepatide | 59 | $60,216 |
| JanuviaSitagliptin Phosphate | 69 | $49,346 |
| TradjentaLinagliptin | 35 | $33,511 |
| Tresiba Flextouch U-100Insulin Degludec | 36 | $30,437 |
| FarxigaDapagliflozin Propanediol | 28 | $23,429 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 17 | $19,442 |
| SynthroidLevothyroxine Sodium | 164 | $15,294 |
| Novolog FlexpenInsulin Aspart | 62 | $14,511 |
| VascepaIcosapent Ethyl | 33 | $14,267 |
| SynjardyEmpagliflozin/Metformin Hcl | 13 | $11,067 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 75 | $10,257 |
| Bydureon BciseExenatide Microspheres | 11 | $9,696 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta, Synjardy | $215 | $197,941241 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $339 | $172,425173 claims |
| Novo NordiskOzempic | $151 | $99,079101 claims |
| MerckJanuvia | $79 | $49,34669 claims |
| AstraZenecaFarxiga | $104 | $23,42928 claims |
| AbbVieSynthroid | $428 | $15,294164 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $32 | $1,638184 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 102 pediatric endocrinology providers in Florida.
Other pediatric endocrinology in Miami Lakes
- Konda ReddyWinter Park$7.3M
- Jennifer MillerGainesville$4.5M
- Dorothy ShulmanTampa$3.5M
- Nelly MaurasJacksonville$2.9M
- Sureka BollepalliTampa$2.8M
- Henry RodriguezTampa$1.7M
- Danielle ReynoldsTampa$1.1M
- Joshua YangOrlando$1.1M
- Larry FoxJacksonville$848K
- Michael HallerGainesville$519K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.